NRSN is trading 5.5% down now at $0.72 after announcing it achieved the primary endpoint in its Phase 2b ALS study, a key milestone for its lead asset PrimeC.
- The clinical success follows recent stock gains fueled by Alzheimer’s biomarker data, a new Japanese patent, and insider-led financing.
- Today’s pullback suggests a sell-the-news reaction as investors reassess near-term risk and potential dilution despite the positive clinical results.